MAPT and tauopathy: Then, to determine whether tau fragments corresponding to proteolytic cleavage by GzmA were present in tauopathy brain, we developed a semi-targeted mass spectrometry methodology that uses synthetic peptides based on the proposed GzmA cleavage sites in tau to direct analysis in a highly sensitive and specific manner.